The Affordable Care Act: Human Immunodeficiency Virus (hiv) Prevention And Public Health Fund Activities
Program activities under this funding will allow for CDC partnership with state and local health departments and other agencies to substantially reduce HIV risk and incidence. Specifically, the program activities may include but are not limited to:
1. Expanded and improved surveillance activities, including a laboratory reporting supplement to the current surveillance program to enable state and local health departments to improve the reporting of HIV laboratory data with special emphasis on CD4 and VL test results.
2. Increased HIV testing and linkage to care services.
3. Comprehensive HIV prevention activities, including the implementation of a structured, evidence-based collection of HIV prevention interventions in a limited number of jurisdictions with the most cases of AIDS. Interventions will include HIV testing, linkage and retention in care, Prevention with Positives including antiretroviral therapy and behavioral interventions, prioritized behavioral interventions for people at highest risk of HIV infection, condom distribution, and enhanced policy, systems, and environmental approaches.
4. Activities to support the above efforts, including program monitoring and evaluation, capacity building, and technical assistance.
Last Known Status
Deleted 02/05/2016 (Not Specified.)
Agency: Department of Health and Human Services
Office: Centers for Disease Control and Prevention
Types of Assistance
Uses and Use Restrictions
Project funds may be used for costs associated with planning, data collection, organizing, and the implementation of program elements to build HIV prevention and public health capacity. Recipients may only expend funds for reasonable program purposes, including personnel, travel, supplies, and services, such as contractual.
Public Health Service Act, Executive Order This program is authorized under Sections 301, 317, 317(k)(2), 318 and 318B of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended, 42 U.S.C 247b,247b(k)(2); Patient Protection and Affordable Care Act - This program is authorized under the Patient Protection and Affordable Care Act (Public Law 111-148), Title IV, Sections 4002, (Prevention and Public Health Fund) for expanded and sustained national investment in prevention and public health programs. , Executive Order This program is authorized under the Patient Protection and Affordable Care Act (Public Law 111-148), Title IV, Sections 4002, (Prevention and Public Health Fund) for expanded and sustained national investment in prevention and public health programs. , Title IV, Section 4002, Public Law 111-148, Stat. 124-1025, 42 U.S.C.
Eligible applicants include state and local governments or their Bona Fide Agents.
State and local health departments, U.S. Territories, and the general public will benefit.
No credentials or documentation are required. This program is excluded from coverage under OMB Circular No. A-87. Costs will be determined by 2 CFR Part 230, Cost Principles for Non-Profit Organizations (OMB Circular A-122). This program is excluded from coverage under OMB Circular No. A-87.
Application and Award Process
Preapplication coordination is not applicable. Environmental impact information is not required for this program. This program is excluded from coverage under E.O. 12372.
This program is excluded from coverage under OMB Circular No. A-102. This program is excluded from coverage under OMB Circular No. A-110. Applicants must download application forms from www.Grants.gov. Applications must be submitted electronically at www.Grants.gov. If an applicant does not have access to the Internet, or if they have difficulty accessing the forms on-line, contact the CDC Procurement and Grants Office Technical Information Management Section (PGO-TIMS) staff. For this, or further assistance, contact PGO-TIMS: Telephone (770) 488-2700, Email: PGOTIM@cdc.gov
Successful applicants will receive a Notice of Award (NoA) from the CDC Procurement and Grants Office. The NoA shall be the only binding, authorizing document between the recipient and CDC. The NoA will be signed by an authorized Grants Management Officer and emailed to the program director and a hard copy mailed to the recipient fiscal officer identified in the application.
Unsuccessful applicants will receive notification of the results of the application review by mail.
Contact the headquarters or regional office, as appropriate, for application deadlines.
Range of Approval/Disapproval Time
From 90 to 120 days. About 120 days from receipt of application.
Renewals will be based upon the conditions in the funding announcement and are subject to the availability of funds under the Patient Protection and Affordable Care Act.
Formula and Matching Requirements
This program has no statutory formula.
This program has no matching requirements.
This program does not have MOE requirements.
Length and Time Phasing of Assistance
Financial assistance is available for a 12-month budget period. See the following for information on how assistance is awarded/released: See the FOA for information on how assistance is awarded/released.
Post Assistance Requirements
The reporting schedule will be based on the requirements listed in the funding announcement. In most cases, funded applicants must provide an interim and annual progress report. Where applicable, the interim progress report is due no less than 90 days before the end of the specified budget period. Where applicable, the Interim Progress Report (IPR) will serve as the non-competing continuation application. Financial Status Reports (SF 269) are required no more than 90 days after the end of the budget period. Final financial status and progress reports are due no later than 90 days after the end of the project period. The reporting schedule will be based on the requirements listed in the funding announcement. In most cases, funded applicants must provide an interim and annual progress report. Where applicable, the interim progress report is due no less than 90 days before the end of the specified budget period. Where applicable, the Interim Progress Report (IPR) will serve as the non-competing continuation application. Financial Status Reports (SF 269) are required no more than 90 days after the end of the budget period. Final financial status and progress reports are due no later than 90 days after the end of the project period. Performance monitoring is not applicable.
In accordance with the provisions of OMB Circular No. A-133 (Revised, June 27, 2003), "Audits of States, Local Governments, and Non-Profit Organizations," nonfederal entities that expend financial assistance of $500,000 or more in Federal awards will have a single or a program-specific audit conducted for that year. Nonfederal entities that expend less than $500,000 a year in Federal awards are exempt from Federal audit requirements for that year, except as noted in Circular No. A-133. Records must be available for review or audit by appropriate officials of the Federal agency, pass-through entity, and General Accounting Office (GAO). The grantee is to also ensure that the sub-recipients receiving CDC funds also meet these requirements (if total Federal grant or grants funds received exceed $500,000). The grantee should include this requirement in all sub-recipient contracts.
Financial records, supporting documents, statistical records, and all other records pertinent to the program shall be retained for a minimum of 3 years, or until completion and resolution of any audit in process or pending resolution. In all cases records must be retained until resolution of any audit questions. Property records must be retained in accordance with 45 CFR 92.42.
(Cooperative Agreements) FY 13 $0; FY 14 est $0; and FY 15 est $0 - This CFDA category was added to the DHAP CFDA Report. DHAP received Prevention and Public Health Funds (PPHF) in FY 2010 and published PS10-10181 - Enhanced Comprehensive HIV Prevention Planning and Implementation for Metropolitan Statistical Areas Most Affected by HIV/AIDS. A subsequent FOA (PS11-1117) was funded with non-PPHF funds and published in FY 2011 under this CFDA category with a 2-year project period. The project, funded with FY2012 funding, ended 9/30/2013, per Program.
Range and Average of Financial Assistance
Awards will range from approximately $85,000 to $1,700,000 with an average of approximately $500,000.
Regulations, Guidelines and Literature
Regulations governing this program are published under 42 CFR 55b. Guidelines are available. 45 CFR 74 and 45 CFR 92, and also HHS Grants Policy Statement, as applicable, at http://www.ahrq.gov/fund/hhspolicy.htm.
Regional or Local Office
Elizabeth Wolfe 1600 Clifton Road, NE, Mailstop E-07, Atlanta, Georgia 30333 Email: email@example.com
Phone: (404) 639-8531
Examples of Funded Projects
Criteria for Selecting Proposals
Applications will be reviewed for completeness by the Procurement and Grants Office (PGO) staff and for responsiveness jointly by Division of HIV/AIDS Prevention (DHAP), NCHHSTP and PGO. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance through the review process. Applicants will be notified the application did not meet submission requirements.
CDC will conduct a review to evaluate complete and responsive applications according to the criteria listed in Section V. Application and Submission Information, subsection “Evaluation Criteria” within the individual funding announcement. Applicants will be notified if their application did not meet program requirements.